Year: 2014
Type: article
Abstract: To the Editor: Current control rates are far below the Healthy People goal of 50%, which was originally set as the year 2000 goal and has since been extended.1 Treatment has generated a benefit-to-cost ratio of at least 6:1, but much more can be achieved.More effective use of antihypertensive medication would have an impact on mortality akin to eliminating all deaths from medical errors or accidents.2 Poor adherence to antihypertensive therapy is a major cause of lack of blood pressure control.At the core of clinical decisions for individual management is a need for ready identification of individuals who remain uncontrolled, or appear to require a considerable pharmaceutical burden to achieve control, and whether nonadherence or pharmacologic unresponsiveness is the root cause.We wish to describe the first use of a commercially available digital health feedback system (Helius; Proteus Digital Health, Inc, Redwood City, CA) to assess hypertension therapy.It consists of a poppy-sized ingestible sensor made of foodstuff, and a wearable sensor (also called "Patch") that may be utilized for 7day wear during all activities including exercising and bathing.The patch automatically logs and stores the dates and times of ingestible sensor ingestion and activities of daily living.The Patch is capable of automatically transmitting its stored data to a compatible computerized device for display, or having its stored data downloaded after completion of its use.We invited 8 of our patients who were taking chronic antihypertensive treatment to utilize the system for a 2week period.Patients wore the wearable sensor continuously, with replacement after 1 week, and ingested the ingestible sensor daily whenever they took their prescribed antihypertensive drugs.Ingestible sensor use was downloaded from each Patch after its use for correlation with blood pressure determinations that were made at the time of clinic visits before, during, and at the end of system use.Our patients included 5 men, aged 49 to 62 years, with essential hypertension.All patients were prescribed long-term antihypertensive treatment.After 2 weeks of product use, taking adherence (ie, number of ingestible sensors detected divided by the total number prescribed) ranged from 70% to 100%, and timing adherence (ie, number of ingestible sensors
Source: Journal of Clinical Hypertension
DOI: 10.1111/jch.12246
Authors: Peter Godbehere, Phillip Wareing
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2049768988